• Vaccine Name: cAdVax-based bivalent ebola virus vaccine (Sudan and Zaire species)
• Target Pathogen: Ebola virus
• Target Disease: Ebola hemorrhagic fever
• Vaccine Ontology ID: VO_0004647
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Human
• GP from Sudan ebolavirus gene engineering:
  • Type: Recombinant protein preparation
  • Description: The gene was inserted into a single complex adenovirus-based vaccine (cAdVax) vector (Wang et al., 2006).
  • Detailed Gene Information: Click Here.
• GP from Zaire ebolavirus gene engineering:
  • Type: Recombinant protein preparation
  • Description: The gene was inserted into a single complex adenovirus-based vaccine (cAdVax) vector (Wang et al., 2006).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001086
• Preparation: The bivalent cAdVaxE(GPs/z) vaccine includes the SEBOV glycoprotein (GP) and ZEBOV GP genes together in a single complex adenovirus-based vaccine (cAdVax) vector (Wang et al., 2006).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccine Immune Response Type: VO_0003057
• Immune Response: Vaccination of mice with the bivalent cAdVaxE(GPs/z) vaccine led to efficient induction of EBOV-specific antibody and cell-mediated immune responses to both species of EBOV (Wang et al., 2006).
• Challenge Protocol: Mice were challenged with a lethal dose of ZEBOV (30,000 times the 50% lethal dose) (Wang et al., 2006).
• Efficacy: the cAdVax technology demonstrated induction of a 100% protective immune response in mice, as all vaccinated C57BL/6 and BALB/c mice survived challenge with a lethal dose of ZEBOV (Wang et al., 2006).